ALGN vs. MDGL: A Head-to-Head Stock Comparison

Updated on July 7, 2025

Here’s a clear look at ALGN and MDGL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

ALGN’s market capitalization of 14.27 billion USD is substantially larger than MDGL’s 6.64 billion USD, indicating a significant difference in their market valuations.

ALGN has a positive beta (1.64), indicating it generally moves with the broader market, whereas MDGL has a negative beta (-1.08), often moving inversely, which can offer diversification or hedging benefits.

Symbol	ALGN	MDGL
Company Name	Align Technology, Inc.	Madrigal Pharmaceuticals, Inc.
Country	US	US
Sector	Healthcare	Healthcare
Industry	Medical - Devices	Biotechnology
CEO	Joseph M. Hogan	William J. Sibold
Price	196.82 USD	298.87 USD
Market Cap	14.27 billion USD	6.64 billion USD
Beta	1.64	-1.08
Exchange	NASDAQ	NASDAQ
IPO Date	January 30, 2001	February 6, 2007
ADR	No	No

Historical Performance

This chart compares the performance of ALGN and MDGL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALGN vs. MDGL: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALGN

10.67%

Medical - Devices Industry

Max: 49.04%
Q3: 9.53%
Median: -7.46%
Q1: -32.83%
Min: -82.64%

In the upper quartile for the Medical - Devices industry, ALGN’s Return on Equity of 10.67% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

MDGL

-50.54%

Biotechnology Industry

Max: 72.39%
Q3: -6.30%
Median: -32.82%
Q1: -68.26%
Min: -147.61%

MDGL has a negative Return on Equity of -50.54%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ALGN vs. MDGL: A comparison of their ROE against their respective Medical - Devices and Biotechnology industry benchmarks.

Return on Invested Capital

ALGN

9.78%

Medical - Devices Industry

Max: 21.88%
Q3: 6.63%
Median: -1.11%
Q1: -21.08%
Min: -51.95%

In the upper quartile for the Medical - Devices industry, ALGN’s Return on Invested Capital of 9.78% signifies a highly effective use of its capital to generate profits when compared to its peers.

MDGL

-51.26%

Biotechnology Industry

Max: 48.74%
Q3: -10.68%
Median: -31.65%
Q1: -52.92%
Min: -113.69%

MDGL has a negative Return on Invested Capital of -51.26%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ALGN vs. MDGL: A comparison of their ROIC against their respective Medical - Devices and Biotechnology industry benchmarks.

Net Profit Margin

ALGN

10.29%

Medical - Devices Industry

Max: 44.80%
Q3: 9.77%
Median: -5.53%
Q1: -29.37%
Min: -87.68%

A Net Profit Margin of 10.29% places ALGN in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.

MDGL

-123.38%

Biotechnology Industry

Max: 87.75%
Q3: -5.05%
Median: -103.44%
Q1: -1,032.77%
Min: -2,366.07%

MDGL has a negative Net Profit Margin of -123.38%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ALGN vs. MDGL: A comparison of their Net Profit Margin against their respective Medical - Devices and Biotechnology industry benchmarks.

Operating Profit Margin

ALGN

14.69%

Medical - Devices Industry

Max: 30.13%
Q3: 13.12%
Median: 3.47%
Q1: -24.42%
Min: -80.56%

An Operating Profit Margin of 14.69% places ALGN in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

MDGL

-133.95%

Biotechnology Industry

Max: 87.75%
Q3: -3.28%
Median: -115.26%
Q1: -1,188.86%
Min: -2,943.30%

MDGL has a negative Operating Profit Margin of -133.95%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ALGN vs. MDGL: A comparison of their Operating Margin against their respective Medical - Devices and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	ALGN	MDGL
Return on Equity (TTM)	10.67%	-50.54%
Return on Assets (TTM)	6.71%	-39.29%
Return on Invested Capital (TTM)	9.78%	-51.26%
Net Profit Margin (TTM)	10.29%	-123.38%
Operating Profit Margin (TTM)	14.69%	-133.95%
Gross Profit Margin (TTM)	69.87%	96.67%

Financial Strength

Current Ratio

ALGN

1.21

Medical - Devices Industry

Max: 12.68
Q3: 6.30
Median: 4.05
Q1: 1.85
Min: 0.01

ALGN’s Current Ratio of 1.21 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

MDGL

5.91

Biotechnology Industry

Max: 28.73
Q3: 13.97
Median: 6.31
Q1: 3.60
Min: 0.02

MDGL’s Current Ratio of 5.91 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ALGN vs. MDGL: A comparison of their Current Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Debt-to-Equity Ratio

ALGN

0.03

Medical - Devices Industry

Max: 2.34
Q3: 1.09
Median: 0.37
Q1: 0.08
Min: 0.00

Falling into the lower quartile for the Medical - Devices industry, ALGN’s Debt-to-Equity Ratio of 0.03 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

MDGL

0.17

Biotechnology Industry

Max: 0.46
Q3: 0.22
Median: 0.06
Q1: 0.02
Min: 0.00

MDGL’s Debt-to-Equity Ratio of 0.17 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALGN vs. MDGL: A comparison of their D/E Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Interest Coverage Ratio

ALGN

Medical - Devices Industry

Max: 18.18
Q3: 7.53
Median: 0.85
Q1: -9.80
Min: -33.94

Interest Coverage Ratio data for ALGN is currently unavailable.

MDGL

-30.09

Biotechnology Industry

Max: 108.32
Q3: -0.55
Median: -8.49
Q1: -74.83
Min: -168.36

MDGL has a negative Interest Coverage Ratio of -30.09. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ALGN vs. MDGL: A comparison of their Interest Coverage against their respective Medical - Devices and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	ALGN	MDGL
Current Ratio (TTM)	1.21	5.91
Quick Ratio (TTM)	1.08	5.58
Debt-to-Equity Ratio (TTM)	0.03	0.17
Debt-to-Asset Ratio (TTM)	0.02	0.12
Net Debt-to-EBITDA Ratio (TTM)	-0.94	0.17
Interest Coverage Ratio (TTM)	--	-30.09

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALGN and MDGL. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALGN vs. MDGL: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALGN vs. MDGL: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALGN vs. MDGL: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALGN

0.00%

Medical - Devices Industry

Max: 3.57%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MDGL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALGN vs. MDGL: A comparison of their Dividend Yield against their respective Medical - Devices and Biotechnology industry benchmarks.

Dividend Payout Ratio

ALGN

0.00%

Medical - Devices Industry

Max: 102.12%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MDGL

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALGN vs. MDGL: A comparison of their Payout Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	ALGN	MDGL
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio

ALGN

35.35

Medical - Devices Industry

Max: 90.56
Q3: 56.92
Median: 43.19
Q1: 21.79
Min: 5.55

ALGN’s P/E Ratio of 35.35 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

MDGL

-16.86

Biotechnology Industry

Max: 78.44
Q3: 48.98
Median: 20.50
Q1: 12.64
Min: 2.14

MDGL has a negative P/E Ratio of -16.86. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ALGN vs. MDGL: A comparison of their P/E Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Forward P/E to Growth Ratio

ALGN

3.34

Medical - Devices Industry

Max: 6.56
Q3: 3.52
Median: 2.22
Q1: 0.55
Min: 0.03

ALGN’s Forward PEG Ratio of 3.34 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

MDGL

-0.91

Biotechnology Industry

Max: 2.29
Q3: 1.10
Median: 0.49
Q1: 0.16
Min: 0.02

MDGL has a negative Forward PEG Ratio of -0.91. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

ALGN vs. MDGL: A comparison of their Forward PEG Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Price-to-Sales Ratio

ALGN

3.58

Medical - Devices Industry

Max: 15.74
Q3: 8.12
Median: 3.40
Q1: 2.37
Min: 0.42

ALGN’s P/S Ratio of 3.58 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

MDGL

20.91

Biotechnology Industry

Max: 110.90
Q3: 59.76
Median: 11.33
Q1: 4.45
Min: 0.17

MDGL’s P/S Ratio of 20.91 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALGN vs. MDGL: A comparison of their P/S Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Price-to-Book Ratio

ALGN

3.82

Medical - Devices Industry

Max: 16.65
Q3: 8.03
Median: 3.73
Q1: 1.92
Min: 0.65

ALGN’s P/B Ratio of 3.82 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

MDGL

9.29

Biotechnology Industry

Max: 15.78
Q3: 7.44
Median: 3.31
Q1: 1.58
Min: 0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ALGN vs. MDGL: A comparison of their P/B Ratio against their respective Medical - Devices and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	ALGN	MDGL
Price-to-Earnings Ratio (P/E, TTM)	35.35	-16.86
Forward PEG Ratio (TTM)	3.34	-0.91
Price-to-Sales Ratio (P/S, TTM)	3.58	20.91
Price-to-Book Ratio (P/B, TTM)	3.82	9.29
Price-to-Free Cash Flow Ratio (P/FCF, TTM)	22.62	-16.53
EV-to-EBITDA (TTM)	16.80	-17.47
EV-to-Sales (TTM)	3.39	20.71